Starting July 1, 2026, eligible Medicare Part D enrollees can get Wegovy, Zepbound, or Foundayo for $50 a month through the new Medicare GLP-1 Bridge. Trinity Family Medicine physicians explain who qualifies, what's covered, and how the prior authorization works.
By Dr. Casey Dean, DO · Board-Certified Family Medicine Physician (ABFM) · Published 2026-06-25 · Updated 2026-06-25
Written by the physicians at Trinity Family Medicine — Dr. Casey Dean, DO & Dr. Kathryn Kline, MD, Board-Certified Family Medicine Physicians. Last medically reviewed: June 2026.
GLP-1 weight loss medications like Wegovy and Zepbound can cost $1,000 to $1,600 a month without insurance — prices that put them out of reach for most people. But starting July 1, 2026, the Medicare GLP-1 Bridge program changes that. Eligible Medicare beneficiaries can now get FDA-approved weight loss medications for just $50 a month.
For the estimated 14 million Medicare beneficiaries living with obesity, this is the first time the federal government has offered meaningful access to these drugs specifically for weight loss. Here is what you need to know — from physicians who prescribe [GLP-1 medications](/glp1) every day and who will handle the prior authorization (the approval paperwork your doctor submits) for you.
No. If you have type 2 diabetes, GLP-1 medications are already a covered Part D indication — meaning your regular Medicare drug plan should cover them. The Bridge program is specifically for beneficiaries who need GLP-1s for weight loss and cannot access them through standard Part D coverage. If you have diabetes and are struggling with Part D coverage, talk to your plan about formulary options.
A family medicine physician can prescribe GLP-1 weight loss medications and submit the Medicare GLP-1 Bridge prior authorization. You do not need a referral to an endocrinologist or obesity medicine specialist. Any licensed prescriber — MD, DO, NP, or PA — can participate as long as they are in good standing with CMS.
The Medicare GLP-1 Bridge is a temporary demonstration. CMS originally planned a longer-term program called the BALANCE Model, but that has been delayed indefinitely. If the Bridge program ends without a replacement, you would need to either continue the medication through a manufacturer savings program, pay out of pocket, or discuss alternatives with your doctor. We recommend using the 18-month program window to achieve meaningful weight loss and establish lifestyle habits that help maintain your progress.
No. The $50 copay does not count toward your TrOOP — your true out-of-pocket spending threshold under Medicare Part D. It also does not apply to your Part D deductible. The Bridge program operates separately from your standard Part D benefit.
Yes, but switching medications requires a new prior authorization. If you stay on the same drug, your original approval covers all refills and dose adjustments through December 31, 2027. If side effects or other factors prompt a change, your doctor will submit a new prior authorization for the different medication.
Yes. The prior authorization form can be submitted electronically, and your doctor can evaluate your eligibility, review your medical history, and prescribe your medication entirely through a telehealth visit. You do not need an in-person appointment to participate in the Medicare GLP-1 Bridge program.